Cargando…

1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia

BACKGROUND: Antibiotic resistance harbored in gut microbiome contributes to the emergence of multi–drug-resistant organisms (MDRO). Pediatric leukemia patients typically receive extensive antibiotics and are at higher risk for infection due to MDRO. METHODS: A prospective cohort of children (n = 242...

Descripción completa

Detalles Bibliográficos
Autores principales: Margolis, Ellie, Hakim, Hana, Yao, Jiangwei, Rosch, Jason, Tang, Li, Sun, Yilun, Dallas, Ronald, Wolf, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252898/
http://dx.doi.org/10.1093/ofid/ofy209.156
_version_ 1783373371276263424
author Margolis, Ellie
Hakim, Hana
Yao, Jiangwei
Rosch, Jason
Tang, Li
Sun, Yilun
Dallas, Ronald
Wolf, Joshua
author_facet Margolis, Ellie
Hakim, Hana
Yao, Jiangwei
Rosch, Jason
Tang, Li
Sun, Yilun
Dallas, Ronald
Wolf, Joshua
author_sort Margolis, Ellie
collection PubMed
description BACKGROUND: Antibiotic resistance harbored in gut microbiome contributes to the emergence of multi–drug-resistant organisms (MDRO). Pediatric leukemia patients typically receive extensive antibiotics and are at higher risk for infection due to MDRO. METHODS: A prospective cohort of children (n = 242) with acute lymphoblastic leukemia self-collected stool samples at diagnosis and after induction chemothearpy. A third of patients (n = 69) underwent protocol-driven antibiotic prophylaxis: Levofloxacin (LV) given once neutropenia develops. With neutropenic fever patients on prophylaxis stopped LV and all patients received cefepime. Using metagenomic sequencing, we identified bacterial community composition and after alignment to the Comprehensive Antibiotic Resistance Database were able to determine the presence of bacterial resistance genes in 168 stool samples from 49 patients. RESULTS: Expected changes in the community composition were discovered with LV prophylaxis, including the loss of many Enterobacteriaceae and Enterococcaceae species, offset by increases in Bacteroides species. Unexpectedly, LV prophylaxis reduced the acquisition of VanA cluster of vancomycin resistance genes and did not increase acquisition of β-lactamase or fluoroquinolone (FQ) resistance gene families. CONCLUSION: LV prophylaxis during leukemia treatment imparts predictable changes in gut bacterial communities but counter intuitively decreases antibiotic resistance in the gut microbiome reservoir. The reduction in VanA cluster of genes is likely due to depletion of Enterococcaceae species via direct killing or loss of synergistic partners. The lack of increase in target (FQ) or off-target resistance suggests that prophylaxis altered community selective pressures or prophylaxis drug concentrations were sufficient to limit the outgrowth of resistant mutants. DISCLOSURES: J. Wolf, Karius Inc.: Investigator, Research support.
format Online
Article
Text
id pubmed-6252898
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62528982018-11-28 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia Margolis, Ellie Hakim, Hana Yao, Jiangwei Rosch, Jason Tang, Li Sun, Yilun Dallas, Ronald Wolf, Joshua Open Forum Infect Dis Abstracts BACKGROUND: Antibiotic resistance harbored in gut microbiome contributes to the emergence of multi–drug-resistant organisms (MDRO). Pediatric leukemia patients typically receive extensive antibiotics and are at higher risk for infection due to MDRO. METHODS: A prospective cohort of children (n = 242) with acute lymphoblastic leukemia self-collected stool samples at diagnosis and after induction chemothearpy. A third of patients (n = 69) underwent protocol-driven antibiotic prophylaxis: Levofloxacin (LV) given once neutropenia develops. With neutropenic fever patients on prophylaxis stopped LV and all patients received cefepime. Using metagenomic sequencing, we identified bacterial community composition and after alignment to the Comprehensive Antibiotic Resistance Database were able to determine the presence of bacterial resistance genes in 168 stool samples from 49 patients. RESULTS: Expected changes in the community composition were discovered with LV prophylaxis, including the loss of many Enterobacteriaceae and Enterococcaceae species, offset by increases in Bacteroides species. Unexpectedly, LV prophylaxis reduced the acquisition of VanA cluster of vancomycin resistance genes and did not increase acquisition of β-lactamase or fluoroquinolone (FQ) resistance gene families. CONCLUSION: LV prophylaxis during leukemia treatment imparts predictable changes in gut bacterial communities but counter intuitively decreases antibiotic resistance in the gut microbiome reservoir. The reduction in VanA cluster of genes is likely due to depletion of Enterococcaceae species via direct killing or loss of synergistic partners. The lack of increase in target (FQ) or off-target resistance suggests that prophylaxis altered community selective pressures or prophylaxis drug concentrations were sufficient to limit the outgrowth of resistant mutants. DISCLOSURES: J. Wolf, Karius Inc.: Investigator, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6252898/ http://dx.doi.org/10.1093/ofid/ofy209.156 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Margolis, Ellie
Hakim, Hana
Yao, Jiangwei
Rosch, Jason
Tang, Li
Sun, Yilun
Dallas, Ronald
Wolf, Joshua
1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title_full 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title_fullStr 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title_full_unstemmed 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title_short 1771. Gut Resistome Changes in Response to Prophylactic Antibiotic Administration During Chemotherapy in Children With Acute Lymphoblastic Leukemia
title_sort 1771. gut resistome changes in response to prophylactic antibiotic administration during chemotherapy in children with acute lymphoblastic leukemia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252898/
http://dx.doi.org/10.1093/ofid/ofy209.156
work_keys_str_mv AT margolisellie 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT hakimhana 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT yaojiangwei 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT roschjason 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT tangli 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT sunyilun 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT dallasronald 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia
AT wolfjoshua 1771gutresistomechangesinresponsetoprophylacticantibioticadministrationduringchemotherapyinchildrenwithacutelymphoblasticleukemia